Proteomic approaches in neuroblastoma: a complementary clinical platform for the future

Area of Science:

• Pediatric Oncology
• Molecular Biology
• Genomics and Proteomics

Background:

• Neuroblastoma (NB) is a common childhood solid tumor with varied clinical outcomes.
• High-throughput omics technologies have advanced understanding of tumor formation and progression.
• Current NB classification and risk stratification benefit from omics data.

Purpose of the Study:

• To review the application of omics technologies, particularly proteomics, in neuroblastoma research.
• To highlight how NB-directed proteomics can identify novel biomarkers and therapeutic targets.
• To examine the impact of omics in NB and future integration possibilities.

Main Methods:

• Review of existing literature on high-throughput omics and proteomics in neuroblastoma.
• Analysis of specific examples demonstrating the utility of NB-directed proteomics.
• Examination of the impact of omics technologies on NB classification and risk stratification.

Main Results:

• Omics profiles aid in defining neuroblastoma behavior and guiding targeted therapies.
• Proteomics provides a deeper understanding of neuroblastoma's complex biology.
• Specific NB proteomics studies have identified potential novel biomarkers and therapeutic targets.

Conclusions:

• High-throughput omics, especially proteomics, are crucial for advancing neuroblastoma research.
• These technologies enhance the understanding, classification, and treatment of high-risk neuroblastoma.
• Future integration of emerging omics technologies promises further improvements in patient care.